Brett Villagrand, Genentech

Published on: 

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-06-01-2008, Volume 0, Issue 0


Brett Villagrand

Associate Director, Strategy, BioOncology, Genentech

BORN: Australia; has lived in four countries



On brand success:

Herceptin revolutionized the way to treat HER2-positive breast cancer. I've been fortunate enough to work on that brand for the last three years—and to be here at Genentech at the right time. We've been fairly successful, with sales at around $1.3 billion. It's been a roller coaster ride to get there because the brand's more than doubled its growth over the last four or five years. Now we're facing competition for the first time. But despite the entry of a new competitor, we've been able to keep them to less than 5 percent of the market. Far from resting, we've instead put a number of things in place that will help us maintain our leadership role in that area.

Brett Villagrand